Compare FLNG & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLNG | AMLX |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2019 | 2021 |
| Metric | FLNG | AMLX |
|---|---|---|
| Price | $29.48 | $17.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $23.00 | $21.56 |
| AVG Volume (30 Days) | 402.1K | ★ 1.5M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | ★ 9.40% | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $380,786,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.14 | N/A |
| P/E Ratio | $19.72 | ★ N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $21.72 | $5.98 |
| 52 Week High | $33.40 | $18.74 |
| Indicator | FLNG | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 39.73 | 70.97 |
| Support Level | $28.89 | $12.17 |
| Resistance Level | $31.01 | $18.61 |
| Average True Range (ATR) | 0.74 | 0.98 |
| MACD | -0.01 | 0.41 |
| Stochastic Oscillator | 20.16 | 77.45 |
Flex LNG Ltd is an LNG shipping company with a fleet of next-generation LNG carriers with large cargo capacity. The company's fleet consists of several LNG carriers on the water, and all of its vessels are of the latest generation equipped with two-stroke propulsion. Its fleet consists of M-type, Electronically Controlled, Gas Injection (MEGI) LNG carriers and Generation X Dual Fuel (X-DF) LNG carriers, offering improvements in fuel efficiency and thus also carbon footprint compared to the older steam and four-stroke propelled ships. The company has one reportable segment: vessel operations, which generates revenue from the chartering of vessels to customers.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.